Sterling Biotech Limited is engaged in the manufacturing of pharma-grade gelatin and di-calcium phosphate and other pharma products. The Company manufactures gelatin from animal bones. It also manufactures gelatine and its derivatives, resinoids, glues, and allopathic pharmaceutical preparations. It offers anticancer products, such as DOXO Rubicin, which is an anti-cancer chemotherapy drug and is classified as an anthracycline antibiotic; IDARUBICIN, which is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicinis, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, which is a drug used to treat certain cancers, and EPI Rubicin, which is an anthracycline drug used for chemotherapy. Its other products include Lovastatin, which is a cholesterol-lowering agent; DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma, and Simvastatin, which is a lipid-lowering drug used to decrease heart problems in those at a high risk.